Drugs / Fluzone Quadrivalent
Fluzone Quadrivalent
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06229392 | Jun 2026 → Jun 2027 | triple-negative breast carcinoma | Rush University Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03312699 | Sep 2017 → Dec 2023 | hepatitis A virus infection, influenza, typhoid fever | Stanford University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05947071 | Sep 2024 → Jul 2027 expected | disease related to solid organ transplantation, influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT05050318 | Sep → Nov 2021 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT04304768 | Nov 2020 → Jan 2027 expected | immunodeficiency disease | University of Miami | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02908269 | Sep → Dec 2016 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT02563093 | Sep → Dec 2015 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT01946438 | Sep → Dec 2013 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 0 | NCT06067555 Comparator | Jan 2024 → May 2026 overdue | vaccinia | Yale University | Recruiting | No outcome recorded |
| Phase 1 | NCT03926416 Comparator | Feb 2017 → May 2018 | influenza | Codagenix, Inc | Completed | No outcome recorded |
| Phase 2 | NCT02434276 Comparator | May → Aug 2015 | influenza | VaxInnate Corporation | Unknown | No outcome recorded |
| Phase 3 | NCT04120194 Comparator | Oct 2019 → Oct 2020 | influenza | Novavax | Completed | Met primary |
| Phase 3 | NCT03460743 Comparator | Mar 2018 → Oct 2019 | influenza | Laboratorios Liomont | Completed | No outcome recorded |
| Phase 3 | NCT02914275 Comparator | Sep 2016 → Mar 2017 | influenza | Seqirus | Completed | Met primary |
| Phase 3 | NCT02242643 Comparator | Oct 2014 → Mar 2015 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT05514002 Comparator | Sep 2022 → Dec 2023 | influenza | Fatimah Dawood | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 1 release
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluzone Quadrivalent | “Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses...” NCT05947071 ↗17“a United States (US)-licensed comparator IIV4 (C-IIV4; Fluzone® Quadrivalent; n=563) during the Northern Hemisphere 2016-2017 influenza season” PMID 30057283 ↗ Jul 2018 “Treatment Groups Flublok® Quadrivalent (research product) Fluzone® Quadrivalent (active comparator)” NCT03460743 ↗ “a single dose of SD IIV (Fluzone® Quadrivalent by Sanofi Pasteur, 15 µg of HA per strain)” NCT05514002 ↗ “Fluzone® Quadrivalent” NCT05050318 ↗ |
| Known as | C-IIV4 | “a United States (US)-licensed comparator IIV4 (C-IIV4; Fluzone® Quadrivalent; n=563) during the Northern Hemisphere 2016-2017 influenza season” PMID 30057283 ↗ Jul 2018 |
| Known as | Fluzone | “Fluzone® (QuadriFlu - TIV), inactivated, quadrivalent influenza vaccine” NCT03926416 ↗ |
| Known as | Fluzone Quadrivalent, Influenza Vaccine | “Fluzone® Quadrivalent, Influenza Vaccine” NCT02908269 ↗1“Fluzone® Quadrivalent, Influenza Vaccine” NCT02563093 ↗ |
| Known as | Fluzone Quadrivalent, Influenza Virus Vaccine | “Fluzone® Quadrivalent, Influenza Virus Vaccine” NCT01946438 ↗ |
| Known as | QuadriFlu - TIV | “Fluzone® (QuadriFlu - TIV), inactivated, quadrivalent influenza vaccine” NCT03926416 ↗ |
| Modality | Vaccine | “Fluzone Quadrivalent and Fluzone Intradermal vaccines” NCT01946438 ↗ |
| Route | Intramuscular | “administered IM in deltoid region” NCT02242643 ↗ |